Literature DB >> 30235458

Immune Thrombocytopenia - Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI.

Axel Matzdorff, Oliver Meyer, Helmut Ostermann, Volker Kiefel, Wolfgang Eberl, Thomas Kühne, Ingrid Pabinger, Matthias Rummel.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30235458     DOI： 10.1159/000492187

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN： 2296-5270            Impact factor:   2.825


× No keyword cloud information.
  13 in total

1.  Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia.

Authors:  Roszymah Hamzah; Nurasyikin Yusof; Nor Rafeah Tumian; Suria Abdul Aziz; Nur Syahida Mohammad Basri; Tze Shin Leong; Kim Wah Ho; Veena Selvaratnam; Sen Mui Tan; Siti Afiqah Muhamad Jamil
Journal:  J Blood Med       Date:  2022-06-21

2.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

3.  Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand.

Authors:  Philip Yi Choi; Eileen Merriman; Ashwini Bennett; Anoop K Enjeti; Chee Wee Tan; Isaac Goncalves; Danny Hsu; Robert Bird
Journal:  Med J Aust       Date:  2021-10-10       Impact factor: 12.776

4.  A Retrospective Analysis of the Treatment Approach to Immune Thrombocytopenia in the Real World.

Authors:  Diana M Cuervo; Leonardo Enciso
Journal:  Cureus       Date:  2019-10-11

5.  Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.

Authors:  Maria L Lozano; Maria E Mingot-Castellano; María M Perera; Isidro Jarque; Rosa M Campos-Alvarez; Tomás J González-López; Gonzalo Carreño-Tarragona; Nuria Bermejo; Maria F Lopez-Fernandez; Aurora de Andrés; David Valcarcel; Luis F Casado-Montero; Maria T Alvarez-Roman; María I Orts; Silvana Novelli; Nuria Revilla; Jose R González-Porras; Estefanía Bolaños; Manuel A Rodríguez-López; Elisa Orna-Montero; Vicente Vicente
Journal:  Sci Rep       Date:  2019-11-13       Impact factor: 4.379

6.  Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease.

Authors:  Juan Wang; Min Dai; Qiong Fu; Sheng Chen
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

7.  Identification of Candidate Biomarkers for Idiopathic Thrombocytopenic Purpura by Bioinformatics Analysis of Microarray Data.

Authors:  Samira Gilanchi; Hakimeh Zali; Mohammad Faranoush; Mostafa Rezaei Tavirani; Keyvan Shahriary; Mahyar Daskareh
Journal:  Iran J Pharm Res       Date:  2020       Impact factor: 1.696

8.  Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.

Authors:  Divya Samineni; Weize Huang; Leonid Gibiansky; Hao Ding; Rong Zhang; Chunze Li; Arijit Sinha; Richa Rajwanshi; Kathryn Humphrey; Alexandra Bazeos; Ahmed Hamed Salem; Dale Miles
Journal:  Adv Ther       Date:  2021-11-25       Impact factor: 3.845

9.  Severe immune thrombocytopenia in a critically ill COVID-19 patient.

Authors:  Ziga Martincic; Barbara Skopec; Karla Rener; Matej Mavric; Tomaz Vovko; Matjaz Jereb; Milica Lukic
Journal:  Int J Infect Dis       Date:  2020-08-06       Impact factor: 3.623

Review 10.  Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.

Authors:  John D Grainger; Thomas Kühne; Jane Hippenmeyer; Nichola Cooper
Journal:  Ann Hematol       Date:  2021-07-26       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.